文献-镇痛||A型寄生虫的镇痛效果

文献-解热||A型毒可抑制用于膝GABA节阻延治疗多样各地区头痛症

A型可抑制用于膝GABA节阻延治疗多样各地区头痛症：一项随机试验性

Brown背景：Brown

本研究课题宗旨验证可抑制通过持续升温皮肤环境温度延长膝GABA阻延持续时间的结论。作者进行了一项随机、双盲、折衷试验性，研究课题a型可抑制治疗多样各地区头痛症症状膝GABA节阻延的外科。

Brown方法：Brown

采用75 IU A型可抑制（可抑制组）和局部药（折衷组），对下肢多样各地区头痛症症状进行膝GABA节阻延。

主要结果是1个月末后阻延侧足底与对侧足底的比较湿度变化。

次要结果是3个月末后的比较湿度变化以及头痛高强度变化。

Brown结果：Brown

共48名举例来说（N=24/组）被随机平均分配。

可抑制组的比较环境温度增加高于折衷组（分别为1.0±1.3℃ vs. 0.1±0.8℃；差异性：0.9℃[95%CI：0.3～1.5]；P=0.006）。

维持至术后3个月末，为1.1±0.8 ℃ vs.-0.2±1.2 ℃；P=0.009。

此外，与折衷组远比，可抑制组在1个月末（分别为（-2.2±1.0 vs.-1.0±1.6；P=0.003）和3个月末（分别为（-2.0±1.0 vs.-0.6±1.6；P=0.003）时的头痛高强度非常大降低。

不会与可抑制注射具体的严重不当惨案。

Brown结论：Brown

在多样各地区头痛症症状中，使用A型可抑制进行膝GABA节阻延可使患足环境温度升温3个月末，并可减轻头痛。

Botulinum Toxin Type A for Lumbar Sympathetic GanglionBlock in Complex Regional Pain Syndrome: A Randomized Trial

Background: The present study was designed totest the hypothesis that botulinum toxin would prolong the duration of a lumbarsympathetic block measured through a sustained increase in skin temperature.The authors performed a randomized, double-blind, controlled trial to investigatethe clinical outcome of botulinum toxin type A for lumbar sympathetic ganglionblock in patients with complex regional pain syndrome.

Methods: Lumbar sympathetic ganglion block wasconducted in patients with lower-extremity complex regional pain syndrome using75 IU of botulinum toxin type A (botulinum toxin group) and local anesthetic(control group). The primary outcome was the change in the relative temperaturedifference on the blocked sole compared with the contralateral sole at 1postoperative month. The secondary outcomes were the 3-month changes inrelative temperature differences, as well as the pain intensity changes.

Results: A total of 48 participants (N = 24/group)were randomly assigned. The change in relative temperature increase was higherin the botulinum toxin group than in the control group (1.0°C ± 1.3 vs. 0.1°C ±0.8, respectively; difference: 0.9°C [95% CI, 0.3 to 1.5]; P = 0.006), whichwas maintained at 3 months (1.1°C ± 0.8 vs. -0.2°C ± 1.2, respectively; P =0.009). Moreover, pain intensity was greatly reduced in the botulinum toxingroup compared with the control group at 1 month (-2.2 ± 1.0 vs. -1.0 ± 1.6,respectively; P = 0.003) and 3 months (-2.0 ± 1.0 vs. -0.6 ± 1.6, respectively;P = 0.003). There were no severe adverse events pertinent to botulinum toxininjection.

Conclusions: In patients with complex regionalpain syndrome, lumbar sympathetic ganglion block using botulinum toxin type Aincreased the temperature of the affected foot for 3 months and also reducedthe pain.